SOURCE: SkyePharma PLC

January 09, 2007 02:01 ET

SkyePharma PLC announces Injectable Sale & Placing

London, UK -- (MARKET WIRE) -- January 9, 2007 --

FOR IMMEDIATE RELEASE                                9  JANUARY 2007
London, England, 9 January, 2007 - SkyePharma PLC (LSE: SKP; NASDAQ: SKYE) today announces the following:
-    The proposed sale of its Injectable Business* to Blue          
     Acquisition Corp ("Purchaser") for a total consideration which 
     could exceed US$82 million, much of which depends on the       
     completion of the development and substantial future sales of  
     DepoBupivacaine(TM). The consideration includes an initial       
     payment of US$20 million (GBP10.2 million) (less costs, US$2   
     million (GBP1.0 million) paid into escrow, a working capital   
     adjustment and certain liabilities), up to US$62 million       
     (GBP31.7 million) of contingent milestone payments, plus a     
     percentage of sales of certain future products for a defined   
     period of time. In addition, the Injectable Business is        
     retaining responsibility for certain royalty-related payments  
     which, when made, will reduce the Continuing Group's debt to   
     Paul Capital.                                                  
-    Placing of ordinary shares, subject to disapplication of       
     pre-emption rights, to certain institutional shareholders,     
     raising GBP14.8 million (net of expenses) (the "Placing").     
-    Both the Disposal and Placing are subject to shareholder       
     approvals which are inter-conditional. An EGM to approve the   
     Disposal and Placing will be held around the beginning of      
     February 2007.                                                 
-    The proposed restructuring of the existing secured financing   
     facility with Paul Capital to a fixed amortisable note ("Note")
     of US$92.5 million (GBP47.3 million) with up to an additional  
     US$12.5 million (GBP6.4 million) payable if worldwide sales of 
     DepoDur(TM) (a product of the Injectable Business) reach       
     certain thresholds. The amounts payable by the Continuing Group
     under the Note will be reduced to the extent of payments made  
     to Paul Capital by the Injectable Business after the Disposal. 
     The total net present value of the maximum Note (without       
     allowing for the benefit of any future royalty-related payments
     by the Injectable Business) is approximately GBP33 million. The
     value of the Paul Capital obligations in the Group's balance   
     sheet as at 30 June 2006 was GBP42.0 million.                  
-    Taking account of the new committed financing of approximately 
     GBP35 million announced on 27 December 2006 the total          
     additional funds available to the Group in the short term would
     amount to approximately GBP53 million (net of costs).          
-    The Disposal will eliminate the significant cash costs of      
     operating and developing the Injectable Business. The Directors
     believe that, once these transactions are concluded, the       
     Continuing Group will have a sound financial foundation on     
     which to build its future and continue to execute its strategy 
     of focussing on growing its pipeline of oral and inhalation    
A circular to shareholders setting out the reasons for and background to the Disposal and the Placing will be sent to shareholders shortly.

Further details of this announcement are set out below.

*For the six months ended 30 June 2006, the Injectable Division, which comprises the Injectable Business together with an allocation of corporate and other Group costs, assets and liabilities, generated revenues of GBP3.9 million and an operating loss of GBP11.7 million. Its products include DepoCyt®, a treatment for a lymphomatous meningitis, and DepoDur™ for post operative pain.

The ordinary shares in the Placing have not been and will not be registered under the US Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Frank Condella, SkyePharma's Chief Executive, said:

"At the beginning of 2006, we set out several objectives including: the licensing of Flutiform™, our key inhalation product, and the disposal of our Injectable Business.

"In May and September we outlicensed Flutiform™ in the US and Europe, respectively. Today we are announcing the planned sale of the Injectable Business for an initial consideration of US$20 million together with contingency milestone and sales-related payments which could be substantial if DepoBupivacaine™ fulfils its potential under the new ownership.

"The proposed Disposal will relieve the Company of a significant cash burn due to operating losses and the potential costs of future development and capital expenditure of the Injectable Business.

"The Disposal, Placing and Paul Capital Refinancing, along with the GBP35 million CRC Financing announced on 27 December 2006, will put SkyePharma in a good position to build future value by further developing our strategic oral and inhalation products."

Certain statements in this news release are forward-looking statements and are made in reliance on the safe harbour provisions of the US Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will materialize. Because the expectations are subject to risks and uncertainties, actual results may vary significantly from those expressed or implied by the forward-looking statements based upon a number of factors, which are described in SkyePharma's 20-F and other documents on file with the US Securities and Exchange Commission. Factors that could cause differences between actual results and those implied by the forward-looking statements contained in this news release include, without limitation, risks related to the development of new products, risks related to obtaining and maintaining regulatory approval for existing, new or expanded indications of existing and new products, risks related to SkyePharma's ability to manufacture products on a large scale or at all, risks related to SkyePharma's and its marketing partners' ability to market products on a large scale to maintain or expand market share in the face of changes in customer requirements, competition and technological change, risks related to regulatory compliance, the risk of product liability claims, risks related to the ownership and use of intellectual property, and risks related to SkyePharma's ability to manage growth. SkyePharma undertakes no obligation to revise or update any such forward-looking statement to reflect events or circumstances after the date of this release.

The information contained herein does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction.

These materials are not an offer for sale of securities in the United States. Securities may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933. The Company does not intend to register any portion of such offering in the United States or to conduct a public offering of the ordinary shares in the United States.

For further information please contact:
SkyePharma PLC                                  +44 207 491 1777
Frank Condella, Chief           until noon GMT: +44 207 466 5000
Executive Officer                                               
                                    thereafter: +44 207 491 1777
Ken Cunningham, Chief                                           
Operating Officer                                               
Peter Grant, Finance            until noon GMT: +44 207 466 5000
                                    thereafter: +44 207 491 1777
Buchanan Communications                         +44 207 466 5000
Tim Anderson / Mark                                             
Court / Rebecca Skye                                            
Trout Group (US)                                                
Seth Lewis                                     +(1) 617-583-1308

About SkyePharma

SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technologies that provide easier-to-use and more effective drug formulations. There are now eleven approved products incorporating SkyePharma's technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information, visit

About Blue Acquistion Corp.

Blue Acquisition Corp., a Delaware USA, corporation is controlled and funded by a group of financial investors including MPM Capital, OrbiMed and Sanderling Ventures, which led the transaction.

                This information is provided by RNS
     The company news service from the London Stock Exchange